Novo, Sanofi win diabetes approvals

FDA approved two combination therapies to treat Type II diabetes, Xultophy 100/3.6 insulin degludec/liraglutide from Novo Nordisk A/S (CSE:NVO; NYSE:NVO)

Read the full 209 word article

User Sign In